Patents Assigned to Universität Zurich
-
Patent number: 7120481Abstract: A probe and an apparatus for cerebral diagnostics and therapy, in particular for measuring absolute values of regional cerebral flow (CBF) and cerebral oxygenation. The probe is inserted through a burr hole in the skull and comprises illuminating device, light receiving device and a coating encapsulating said illuminating device and said light receiving means. The coating has a longitudinal shape and is adapted to fit through a burr hole in the skull. The coating is further adapted to slide between the skull and the dura, to be inserted into the ventricular system, and/or to be inserted into the cerebral tissue.Type: GrantFiled: July 19, 2001Date of Patent: October 10, 2006Assignee: Universitat ZurichInventors: Emmaneula Keller, Andreas Nadler, Peter Niederer
-
Patent number: 7091313Abstract: Template-fixed ?-hairpin loop mimetics comprising a template corresponding to one of the structures (a), (b), (c), (d), (e), (f), (g), (h) and a template-fixed chain of 4 to 20 ?-amino acid residues which, if their ?-C atom is asymmetric, have L-configuration can be manufactured by a novel process which is based on a mixed solid- and solution phase synthetic strategy. If desired, this process can be modified to give the enantiomers of these template-fixed ?-hairpin loop mimetics. These enantiomers are novel compounds, and many of said template-fixed ?-hairpin loop mimetics themselves are also novel compounds. The template-fixed ?-hairpin loop mimetics and their enantiomers can mimic flat surfaces of proteins and thus be used to probe large surface protein-protein interactions. Accordingly they can serve as lead finding tools for protein targets where it is difficult to find small-molecular-weight lead compounds.Type: GrantFiled: January 5, 2005Date of Patent: August 15, 2006Assignees: Universitat Zurich, Polyphor AGInventors: John A. Robinson, Daniel Obrecht
-
Patent number: 7075130Abstract: A photosensitive device with a photodiode and an amplifier is disclosed. The diode is in series with a feedback transistor which forces the voltage derived from the photocurrent to be a logarithmic function of the light intensity. A current mirror is provided which controls the bias current to the amplifier to be proportional to the photocurrent. This arrangement ensures that the amplifier, just as the voltage derived from the photocurrent, becomes faster with increasing light intensity and therefore prevents an unnecessarily high power consumption at low light intensities.Type: GrantFiled: September 19, 2002Date of Patent: July 11, 2006Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Tobias Delbrück, Shih-Chii Liu, Samual Zahnd, Patrick Lichtsteiner
-
Publication number: 20060127352Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.Type: ApplicationFiled: October 25, 2005Publication date: June 15, 2006Applicants: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey Hubbell, Donald Elbert, Ronald Schoenmakers
-
Patent number: 7049290Abstract: An isolated polypeptide comprising a peptide which consists of a legless homology domain (HD); wherein the peptide inhibits Lgs function in colon cancer cells; and a composition comprising the same, are disclosed.Type: GrantFiled: July 27, 2001Date of Patent: May 23, 2006Assignee: Universität ZürichInventors: Konrad Basler, Erich Brunner, Barbara Froesch, Thomas Kramps, Oliver Peter
-
Patent number: 6960452Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin-binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would?? Healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: GrantFiled: March 2, 2001Date of Patent: November 1, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Publication number: 20050218892Abstract: A novel magnetic resonance (MR) imaging or spectroscopy method is presented, in which a main magnetic field is generated in an object by a main magnet and superimposed magnetic fields and adiofrequency fields are generated according to an MR sequence for forming images or spectra. Object signals are acquired from the object with at least one object detector during execution of the MR sequence. Further, additional data are acquired from at least one monitoring field probe positioned in the vicinity of and surrounding the object, during execution of the MR sequence. The additional data from the monitoring field probes are used for adjusting the MR sequence such as to correct for imperfections in the field response of the object detectors, and the additional data from the monitoring field probes are used in conjunction with the object signals for reconstruction of the images or spectra.Type: ApplicationFiled: March 31, 2005Publication date: October 6, 2005Applicants: Universitat Zurich, ETH ZurichInventors: Klaas Pruessmann, Nicola De Zanche
-
Patent number: 6894022Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling, and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, enzymatic action, and/or diffusion. In one embodiment, a fusion protein, which contains a crosslinking region, such as a factor XIIIa substrate, and a native protein sequence, such as a bioactive factor, is constructed. Degradable linkages may be included between the crosslinking region and the bioactive factor.Type: GrantFiled: May 1, 2000Date of Patent: May 17, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert
-
Patent number: 6884628Abstract: Multifunctional, polyionic copolymers with molecular architectures and properties optimized for specific applications are synthesized on/or applied to substrate surfaces for analytical and sensing purposes. The coatings are particularly useful for suppression of non-specific interaction, adsorption or attachment of molecular or ionic components present in an analyte solution. Chemical, biochemical or biological groups that are able to recognize, interact with and bind specifically to target molecules in the material containing the analyte to be detected can be coupled to, integrated into, or absorbed to the multifunctional copolymers. These multifunctional copolymer coatings are compatible with a variety of different established methods to detect, sense and quantify the target molecule in an analyte.Type: GrantFiled: April 28, 2000Date of Patent: April 26, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Marcus Textor, Donald L. Elbert, Stephanie Finken, Rolf Hofer, Nicholas D. Spencer, Laurence Ruiz-Taylor
-
Patent number: 6797934Abstract: An optical transient sensor circuit includes a photodiode in series with a MOS feedback transistor connected across a voltage difference. An inverting amplifier having its input connected to the common connection between the photodiode and the MOS feedback transistor and its output connected to an output-node for a measure of the incoming irradiance. A charge/discharge circuit, having an input connected to the output of the inverting amplifier, having an output connected to the gate of the MOS feedback transistor and having a first and second output for half-wave rectified and thresholded contrast encoding measures of positive and negative irradiance transients. A capacitor connected between a constant potential and the gate of the MOS feedback transistor.Type: GrantFiled: May 23, 2002Date of Patent: September 28, 2004Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jörg Kramer, Rahul Sarpeshkar
-
Patent number: 6765088Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.Type: GrantFiled: August 23, 1999Date of Patent: July 20, 2004Assignee: Universität ZürichInventors: Carsten Korth, Beat Stierli, Peter Stregt, Bruno Oesch, Markus Moser
-
Patent number: 6723344Abstract: Matrices that support cell adhesion and growth are disclosed that deliver low heparin-binding affinity growth factor protein peptides in a controlled manner. These matrices comprise covalently or non-covalently bound heparin or heparin-like polymers, which serve to sequester the low heparin-binding affinity growth factor protein peptides within the matrix. The controlled release of some low heparin-binding affinity growth factor or peptides thereof occurs by degradation of some matrix component or dissociation of the low heparin-binding affinity growth factor protein peptides from the bound heparin. This differs from many controlled delivery devices in that release is not controlled solely by diffusion, and the rate of release may therefore be regulated by altering the rate of degradation of the matrix component or the amount of heparin bound within the matrix. The controlled release of such low heparin-binding affinity growth factor proteins such as NGF-&bgr;, NT-3 and BDNF, is demonstrated.Type: GrantFiled: May 3, 2001Date of Patent: April 20, 2004Assignees: Eidgenossische Technische Hochschule, Universitat ZurichInventors: Shelly E. Sakiyama-Elbert, Jeffrey A. Hubbell
-
Publication number: 20040038901Abstract: An isolated polypeptide comprising a peptide which consists of a legless homology domain (HD); wherein the peptide inhibits Lgs function in colon cancer cells; and a composition comprising the same, are disclosed.Type: ApplicationFiled: September 22, 2003Publication date: February 26, 2004Applicant: UNIVERSITAT ZURICHInventors: Konrad Basler, Erich Brunner, Barbara Froesch, Thomas Kramps, Oliver Peter
-
Patent number: 6652902Abstract: Boronic acid containing polymers are used to form bioinert gels and multilayer surface structures. These polymers form crosslinked hydrogels, which are highly swollen in water. The crosslinking can either be chemical or physical. Water soluble polymers containing boronic acid groups, such as phenylboronic acid (PBA), can be physically crosslinked by mixing the polymers in water with other polymers containing hydroxyls or carboxylic acids. Alternatively, surfaces can be treated by stepwise incubation with a solution of the boronic acid containing polymer, followed by incubation with a solution of a diol or carboxylic acid containing polymer. Many successive layers can be generated, increasing the thickness of the formed structure at each step.Type: GrantFiled: December 28, 2001Date of Patent: November 25, 2003Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Donald L. Elbert, Natalie D. Winblade
-
Publication number: 20030187232Abstract: Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g.Type: ApplicationFiled: December 17, 2002Publication date: October 2, 2003Applicant: Eidgenossische Technische Hochschule Zurich Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama-Elbert, Anna Jen
-
Patent number: 6603082Abstract: A device for controlling a physical system, such as a flow of pedestrians, in an extended area is suggested. In comprises a plurality of identical cell units with preferably hexagonal shape. The cell units are assembled in tile-like manner to form a floor. Each cell unit is equipped with a weight sensor, lamps of different colors, and optical communication ports as well as power connectors for connecting it to its neighboring cells. The cell units can be programmed to generate signals that control the physical system, such as signs understood by the pedestrians. Due to its modularity and simple design, the device is easy to install and maintain.Type: GrantFiled: October 10, 2000Date of Patent: August 5, 2003Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Tobias Delbrück, Rodney James Douglas, Pierre Marchal, Paul Verschure, Adrian Maurice Whatley
-
Patent number: 6601459Abstract: Method and apparatus to measure in vitro or in vivo the volumetric flow in blood vessels using a pulsed Doppler instrument which allows assessement of crossectional area and mean velocity for determining the real volumetric flow in the vessel, characterized in that Q = k ⁢ M 1 , 3 M 0 , 3 × A 2 N + 1 A 1 N ⁢ MType: GrantFiled: May 31, 2002Date of Patent: August 5, 2003Assignee: Universitat ZurichInventor: Rolf Jenni
-
Publication number: 20030114413Abstract: The present invention relates to a new essential downstream component of the Wnt/Wingless (Wnt/Wg) signaling pathway and therapeutic and diagnostic applications based thereon. The invention relates to nucleotide sequences of the Drosophila melanogaster legless (lgs) gene, of its encoded proteins, as well as derivatives (e.g., fragments) and analogues thereof. The invention further includes vertebrate and invertebrate homologues of the Lgs protein, comprising proteins that contain a contiguous stretch of amino acids with similarity to the Drosophila lgs gene. The invention further relates to the function of the Drosophila and the human Lgs proteins. Methods for producing the Lgs proteins, derivatives and analogs, e.g., by recombinant means and antibodies to Lgs are provided by the present invention. In addition, the invention also relates to the therapeutic and diagnostic methods and compositions based on Lgs proteins and nucleic acids or fragments thereof.Type: ApplicationFiled: December 19, 2002Publication date: June 19, 2003Applicant: UNIVERSITAT ZURICHInventors: Konrad Basler, Erich Brunner, Barbara Froesch, Thomas Kramps, Oliver Peter
-
Publication number: 20030012818Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF&bgr; superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: ApplicationFiled: April 25, 2002Publication date: January 16, 2003Applicant: Eidgenossische Technische Hochschule Zurich and Universitat ZurichInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey Alan Hubbell, Franz Weber
-
Patent number: 6468731Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: GrantFiled: September 29, 2000Date of Patent: October 22, 2002Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama